Has Kadri Aygen received payments from drug or device companies?

Yes. Drug and device makers reported $1,621 in general payments to Kadri Aygen across 93 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kadri Aygen did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kadri Aygen come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kadri Aygen

Pediatrics · Chester, NJNPI 1497723092

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by GSK at 27.3% of the total. Reporting peaked in 2023 at $463 and has fallen 61.4% since, to $178 in 2025. Among pediatrics clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,621in general payments, 2019–2025

Across 93 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$443
Merck$334
Pfizer$223
Sanofi Pasteur Inc.$132
Takeda Pharmaceuticals U.S.A., Inc.$72
Qiagen, LLC$68
plus $350 from 13 others

What the payments were for

Food & beverage$1,621100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	23	$443
Merck	20	$334
Pfizer	14	$223
Sanofi Pasteur Inc.	7	$132
Takeda Pharmaceuticals U.S.A., Inc.	5	$72
Qiagen, LLC	1	$68
Novo Nordisk	4	$63
Cranial Technologies, Inc	3	$57
Tris Pharma Inc	2	$30
Cumberland Pharmaceuticals, Inc.	2	$30
Neos Therapeutics, LP	2	$28
Shire North American Group Inc	2	$27
Kaleo, Inc.	2	$27
Biomarin Pharmaceutical Inc.	1	$17
Genentech USA, Inc.	1	$15
Sobi, Inc	1	$15
Arbor Pharmaceuticals, Inc.	1	$15
Ironshore Pharmaceuticals Inc.	1	$14
Almatica Pharma LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BEXSERO$114

How this compares

$1,621 in reported general payments places this provider in the 90th percentile of 1,890 pediatrics providers in New Jersey.

See all pediatrics providers in New Jersey →

Other pediatrics in Chester

Steven MateretskyHackensack$290K
Sara RaymondMorristown$288K
Andrew MulbergCamden$264K
Bram GreenbergLakewood$200K
David ApelianBoonton$149K
Christopher AmatoGibbsboro$34K
Syeda Amna HusainMarlboro$27K
Nika DouvikasJersey City$27K
Melanie DegliuominiHackensack$17K
Alexandra LaurenzanoRiver Vale$15K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →